Dr. Eric Chiou, MD
Pediatric Gastroenterology (Pediatric Gastroenterology Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in Texas since 2010, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Gastroenterology Physician primary
TX license N7786 (first issued 2010; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in Houston, TX | 39 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $804 in research payments for these studies, mostly to the institutions running them.
- Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
AbbVie Inc. · Completed · NCT03339128
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.